Vaccine maker Novavax (NASDAQ: NVAX) has had a rollercoaster of a year. In May, the company's shares soared after it ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...

Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.

Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...

Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...